Insider Selling: IDEXX Laboratories, Inc. (NASDAQ:IDXX) Chairman Sells 10,000 Shares of Stock

Share on StockTwits

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Chairman Jonathan W. Ayers sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $272.75, for a total transaction of $2,727,500.00. Following the completion of the transaction, the chairman now directly owns 1,035,942 shares in the company, valued at approximately $282,553,180.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Jonathan W. Ayers also recently made the following trade(s):

  • On Tuesday, August 6th, Jonathan W. Ayers sold 20,000 shares of IDEXX Laboratories stock. The stock was sold at an average price of $262.26, for a total transaction of $5,245,200.00.

Shares of NASDAQ:IDXX opened at $271.30 on Thursday. The company has a debt-to-equity ratio of 4.49, a current ratio of 1.15 and a quick ratio of 0.83. IDEXX Laboratories, Inc. has a 1-year low of $176.11 and a 1-year high of $292.17. The stock has a market capitalization of $23.36 billion, a P/E ratio of 63.69 and a beta of 0.84. The firm’s 50 day moving average price is $279.11.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Thursday, August 1st. The company reported $1.43 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.06. IDEXX Laboratories had a net margin of 17.78% and a return on equity of 765.45%. The business had revenue of $620.10 million for the quarter, compared to the consensus estimate of $627.10 million. During the same quarter in the previous year, the firm earned $1.23 earnings per share. The company’s revenue for the quarter was up 6.8% on a year-over-year basis. As a group, research analysts expect that IDEXX Laboratories, Inc. will post 4.86 EPS for the current year.

A number of large investors have recently modified their holdings of IDXX. American Century Companies Inc. lifted its holdings in IDEXX Laboratories by 111.2% during the first quarter. American Century Companies Inc. now owns 1,483,074 shares of the company’s stock valued at $331,615,000 after purchasing an additional 780,846 shares in the last quarter. Marshall Wace North America L.P. lifted its holdings in IDEXX Laboratories by 1,086.6% during the first quarter. Marshall Wace North America L.P. now owns 404,041 shares of the company’s stock valued at $90,344,000 after purchasing an additional 369,991 shares in the last quarter. Invesco Ltd. lifted its holdings in IDEXX Laboratories by 28.2% during the second quarter. Invesco Ltd. now owns 1,472,407 shares of the company’s stock valued at $405,398,000 after purchasing an additional 323,919 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in IDEXX Laboratories by 36.7% during the first quarter. Principal Financial Group Inc. now owns 1,076,895 shares of the company’s stock valued at $240,793,000 after purchasing an additional 289,063 shares in the last quarter. Finally, Thoroughbred Financial Services LLC lifted its holdings in IDEXX Laboratories by 27,432.9% during the second quarter. Thoroughbred Financial Services LLC now owns 257,433 shares of the company’s stock valued at $25,743,000 after purchasing an additional 256,498 shares in the last quarter. 87.39% of the stock is currently owned by institutional investors and hedge funds.

A number of equities analysts recently issued reports on IDXX shares. Canaccord Genuity reissued a “buy” rating and issued a $285.00 price objective on shares of IDEXX Laboratories in a report on Friday, August 2nd. Bank of America set a $300.00 price objective on shares of IDEXX Laboratories and gave the stock a “buy” rating in a report on Friday, June 21st. BidaskClub downgraded shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Friday, July 26th. Zacks Investment Research raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $271.00 price objective on the stock in a report on Friday, May 3rd. Finally, Stifel Nicolaus raised their price objective on shares of IDEXX Laboratories from $255.00 to $295.00 and gave the stock a “buy” rating in a report on Monday, July 22nd. Seven research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average target price of $281.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Recommended Story: What is the Fibonacci sequence?

Insider Buying and Selling by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Bank of New York Mellon Corp Decreases Stock Holdings in iShares Barclays 1-3 Year Treasry Bnd Fd
Bank of New York Mellon Corp Decreases Stock Holdings in iShares Barclays 1-3 Year Treasry Bnd Fd
Equities Research Analysts’ Price Target Changes for September, 16th
Equities Research Analysts’ Price Target Changes for September, 16th
Investment Analysts’ Updated EPS Estimates for September, 16th
Investment Analysts’ Updated EPS Estimates for September, 16th
Bank of New York Mellon Corp Purchases 65,188 Shares of VANGUARD WHITEH/EMERGING MKT GOVT B
Bank of New York Mellon Corp Purchases 65,188 Shares of VANGUARD WHITEH/EMERGING MKT GOVT B
SunOpta  Stock Rating Lowered by Zacks Investment Research
SunOpta Stock Rating Lowered by Zacks Investment Research
Carrols Restaurant Group  Stock Rating Lowered by Zacks Investment Research
Carrols Restaurant Group Stock Rating Lowered by Zacks Investment Research


© 2006-2019 Ticker Report